Interestingly, low miR-199b levels inversely correlated with SET expression and independently predicted shorter overall and progression-free survival defining a subgroup of metastatic CRC patients with very poor outcome candidate to be treated with SET/PP2A targeting drugs such as FTY720. The gene discussed is PTPA; the disease is colorectal carcinoma.